Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 11/2019

01-11-2019 | Fatty Liver | Concise Research Reports

Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes

Authors: Phuc Le, PhD, MPH, Alexander Chaitoff, MD, MPH, Michael B. Rothberg, MD, MPH, Naim Alkhouri, MD, Arthur McCullough, MD

Published in: Journal of General Internal Medicine | Issue 11/2019

Login to get access

Excerpt

Prediabetes affects 84 million US adults, more than 50% of whom will develop diabetes in 15 years.1 Once patients develop diabetes, up to 75% will have nonalcoholic fatty liver disease (NAFLD), and many of these will develop nonalcoholic steatohepatitis (NASH) and advanced fibrosis.2 However, the burden of NAFLD and associated comorbidities in patients with prediabetes is less well understood. We aimed to estimate the population-based trends in prevalence of concurrent suspected NAFLD, advanced fibrosis and NASH cirrhosis in US adults with prediabetes. …
Literature
1.
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 2015;3(11):866–875.CrossRef
2.
Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–131.CrossRef
3.
Sviklane L, Olmane E, Dzerve Z, Kupcs K, Pirags V, Sokolovska J. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol 2018;33(1):270–276.CrossRef
4.
Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol 2017;112(4):581–587.CrossRef
5.
Stefan N, Fritsche A, Schick F, Haring HU. Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 2016;4(9):789–798.CrossRef
6.
Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105(11):2389–2395.CrossRef
Metadata
Title
Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes
Authors
Phuc Le, PhD, MPH
Alexander Chaitoff, MD, MPH
Michael B. Rothberg, MD, MPH
Naim Alkhouri, MD
Arthur McCullough, MD
Publication date
01-11-2019
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 11/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05163-8

Other articles of this Issue 11/2019

Journal of General Internal Medicine 11/2019 Go to the issue

Letter to the Editor

Longitudinal Continuity

Review Paper

Reasons Patients Choose the Emergency Department over Primary Care: a Qualitative Metasynthesis

OriginalPaper

Prescribing Associated with High-Risk Opioid Exposures Among Non-cancer Chronic Users of Opioid Analgesics: a Social Network Analysis

Original Research

Statin Dosing Instructions, Medication Adherence, and Low-Density Lipoprotein Cholesterol: a Cohort Study of Incident Statin Users

Concise Research Reports

Exploring Disease Representation in Movies

Original Research

Variation in Physicians’ Electronic Health Record Documentation and Potential Patient Harm from That Variation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits